DE69821655T2 - Verwendung von phospholipiden zur herstellung eines arzneimittels zur vorbeugung von adhäsionen - Google Patents
Verwendung von phospholipiden zur herstellung eines arzneimittels zur vorbeugung von adhäsionen Download PDFInfo
- Publication number
- DE69821655T2 DE69821655T2 DE69821655T DE69821655T DE69821655T2 DE 69821655 T2 DE69821655 T2 DE 69821655T2 DE 69821655 T DE69821655 T DE 69821655T DE 69821655 T DE69821655 T DE 69821655T DE 69821655 T2 DE69821655 T2 DE 69821655T2
- Authority
- DE
- Germany
- Prior art keywords
- sapl
- dppc
- use according
- dry powder
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000000843 powder Substances 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 17
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 9
- 238000001356 surgical procedure Methods 0.000 claims abstract description 3
- 239000003795 chemical substances by application Substances 0.000 claims abstract 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 12
- 101000991410 Homo sapiens Nucleolar and spindle-associated protein 1 Proteins 0.000 claims description 8
- 101001095380 Homo sapiens Serine/threonine-protein phosphatase 6 regulatory subunit 3 Proteins 0.000 claims description 8
- 102100030991 Nucleolar and spindle-associated protein 1 Human genes 0.000 claims description 8
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 7
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 6
- 238000009826 distribution Methods 0.000 claims description 6
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 5
- 239000006185 dispersion Substances 0.000 claims description 4
- 239000003380 propellant Substances 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 239000004604 Blowing Agent Substances 0.000 claims description 2
- 150000005828 hydrofluoroalkanes Chemical class 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000012528 membrane Substances 0.000 abstract description 5
- 208000002847 Surgical Wound Diseases 0.000 abstract description 3
- 210000004303 peritoneum Anatomy 0.000 description 6
- 238000005299 abrasion Methods 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 235000021120 animal protein Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- HVVJCLFLKMGEIY-UHFFFAOYSA-N 2,3-dioctadecoxypropyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCCCOCC(COP([O-])(=O)OCC[N+](C)(C)C)OCCCCCCCCCCCCCCCCCC HVVJCLFLKMGEIY-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- -1 HFA-134a or HFC-227 Chemical compound 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BBJQPKLGPMQWBU-UHFFFAOYSA-N Palmitinsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCCCCCCCCC)C2 BBJQPKLGPMQWBU-UHFFFAOYSA-N 0.000 description 2
- 208000031737 Tissue Adhesions Diseases 0.000 description 2
- 210000003815 abdominal wall Anatomy 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- BBJQPKLGPMQWBU-JADYGXMDSA-N cholesteryl palmitate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCC)C1 BBJQPKLGPMQWBU-JADYGXMDSA-N 0.000 description 2
- 150000008282 halocarbons Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002991 molded plastic Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9807298 | 1998-04-03 | ||
| GBGB9807298.6A GB9807298D0 (en) | 1998-04-03 | 1998-04-03 | Medicament |
| PCT/GB1998/003540 WO1999051244A1 (en) | 1998-04-03 | 1998-11-26 | Use of phospholipids for the manufacture of a medicament for the prevention of adhesions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69821655D1 DE69821655D1 (de) | 2004-03-18 |
| DE69821655T2 true DE69821655T2 (de) | 2004-12-23 |
Family
ID=10829890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69821655T Expired - Lifetime DE69821655T2 (de) | 1998-04-03 | 1998-11-26 | Verwendung von phospholipiden zur herstellung eines arzneimittels zur vorbeugung von adhäsionen |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6719960B1 (enExample) |
| EP (1) | EP1069902B1 (enExample) |
| JP (1) | JP4287050B2 (enExample) |
| AT (1) | ATE259234T1 (enExample) |
| AU (1) | AU1251799A (enExample) |
| CA (1) | CA2327693C (enExample) |
| DE (1) | DE69821655T2 (enExample) |
| DK (1) | DK1069902T3 (enExample) |
| ES (1) | ES2214748T3 (enExample) |
| GB (2) | GB9807298D0 (enExample) |
| PT (1) | PT1069902E (enExample) |
| WO (1) | WO1999051244A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9807298D0 (en) | 1998-04-03 | 1998-06-03 | Britannia Pharmaceuticals Ltd | Medicament |
| US6156294A (en) * | 1999-11-28 | 2000-12-05 | Scientific Development And Research, Inc. | Composition and method for treatment of otitis media |
| GB0007150D0 (en) * | 2000-03-24 | 2000-05-17 | Lamellar Therapeutics Limited | Immunotherapeutic methods and compositions |
| WO2002094283A2 (en) * | 2001-05-21 | 2002-11-28 | Britannia Pharmaceuticals Limited | Use of phospholipids in the treatment of degenerative lung disease such as copd or cystic fibrosis and to enhance delivery of drugs |
| GB0115505D0 (en) * | 2001-06-25 | 2001-08-15 | Britannia Pharmaceuticals Ltd | Prevention of surgical adhesions |
| GB0200704D0 (en) * | 2002-01-14 | 2002-02-27 | Britannia Pharmaceuticals Ltd | Use of phospholipids in peritoneal dialysis |
| GB0207653D0 (en) * | 2002-04-03 | 2002-05-15 | Lamellar Therapeutics Ltd | Methods of using lamellar bodies for therapeutic purposes |
| EP1426053A1 (en) * | 2002-12-03 | 2004-06-09 | Fresenius Kabi Deutschland GmbH | Use of amphiphilic lipids for reducing tumor metastasis |
| GB0322448D0 (en) | 2003-09-25 | 2003-10-29 | Lamellar Therapeutics Ltd | Using lamellar bodies to modify linear biological macro molecules |
| ES2336796T3 (es) | 2003-10-07 | 2010-04-16 | Northgate Technologies Incorporated | Sistema para suministrar una sustancia a una cavitacion corporal. |
| EP1680173B1 (en) * | 2003-10-31 | 2011-01-12 | Trudell Medical International | System for manipulating a catheter for delivering a substance to a body cavity |
| GB0426010D0 (en) * | 2004-11-26 | 2004-12-29 | Britannia Pharmaceuticals Ltd | Improvements in or relating to organic materials |
| US8414907B2 (en) | 2005-04-28 | 2013-04-09 | Warsaw Orthopedic, Inc. | Coatings on medical implants to guide soft tissue healing |
| US9119901B2 (en) | 2005-04-28 | 2015-09-01 | Warsaw Orthopedic, Inc. | Surface treatments for promoting selective tissue attachment to medical impants |
| CA2660050A1 (en) | 2006-08-04 | 2008-02-07 | Northgate Technologies Inc. | In-dwelling port for access into a body |
| US8020726B1 (en) * | 2006-10-18 | 2011-09-20 | Sandia Corporation | Powder dispersion system |
| US20080241270A1 (en) * | 2007-03-30 | 2008-10-02 | Neal Robert A | Fluid composition for inhibiting surgical adhesion formation and related method of production |
| US9572595B1 (en) | 2014-03-05 | 2017-02-21 | Northgate Technologies Inc. | In-dwelling port for access into a body |
| GB201511058D0 (en) * | 2015-06-23 | 2015-08-05 | Lamellar Biomedical Ltd | Compositions and methods for using lamellar bodies for therapeutic purposes |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58164513A (ja) * | 1982-03-25 | 1983-09-29 | Teijin Ltd | 肺表面活性物質及びその調製法 |
| DE3229179C2 (de) * | 1982-08-05 | 1986-04-17 | A. Nattermann & Cie GmbH, 5000 Köln | Lungensurfactant |
| GB8613811D0 (en) * | 1986-06-06 | 1986-07-09 | Phares Pharm Res Nv | Composition & method |
| IN166447B (enExample) * | 1985-11-27 | 1990-05-12 | Ethicon Inc | |
| WO1991012026A1 (en) * | 1990-02-14 | 1991-08-22 | Macnaught Pty Limited | Means of reducing surgical adhesions |
| CA2083171C (en) | 1990-05-18 | 2002-09-10 | Kurashima Kazuyoshi | Antasthmatic |
| US5438044A (en) * | 1992-06-30 | 1995-08-01 | Rhone-Poulenc Rorer | Phospholipid composition |
| AU7685798A (en) | 1997-05-29 | 1998-12-30 | Applied Biotechnologies Inc. | Compositions and methods for preventing adhesion |
| GB9807298D0 (en) | 1998-04-03 | 1998-06-03 | Britannia Pharmaceuticals Ltd | Medicament |
-
1998
- 1998-04-03 GB GBGB9807298.6A patent/GB9807298D0/en not_active Ceased
- 1998-11-26 GB GB9825971A patent/GB2335853A/en not_active Withdrawn
- 1998-11-26 WO PCT/GB1998/003540 patent/WO1999051244A1/en not_active Ceased
- 1998-11-26 AU AU12517/99A patent/AU1251799A/en not_active Abandoned
- 1998-11-26 CA CA002327693A patent/CA2327693C/en not_active Expired - Fee Related
- 1998-11-26 US US09/582,286 patent/US6719960B1/en not_active Expired - Fee Related
- 1998-11-26 AT AT98955792T patent/ATE259234T1/de active
- 1998-11-26 EP EP98955792A patent/EP1069902B1/en not_active Expired - Lifetime
- 1998-11-26 DK DK98955792T patent/DK1069902T3/da active
- 1998-11-26 JP JP2000542015A patent/JP4287050B2/ja not_active Expired - Fee Related
- 1998-11-26 PT PT98955792T patent/PT1069902E/pt unknown
- 1998-11-26 DE DE69821655T patent/DE69821655T2/de not_active Expired - Lifetime
- 1998-11-26 ES ES98955792T patent/ES2214748T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| PT1069902E (pt) | 2004-06-30 |
| JP4287050B2 (ja) | 2009-07-01 |
| ATE259234T1 (de) | 2004-02-15 |
| GB2335853A (en) | 1999-10-06 |
| CA2327693A1 (en) | 1999-10-14 |
| GB9825971D0 (en) | 1999-01-20 |
| GB9807298D0 (en) | 1998-06-03 |
| JP2002510638A (ja) | 2002-04-09 |
| AU1251799A (en) | 1999-10-25 |
| EP1069902A1 (en) | 2001-01-24 |
| EP1069902B1 (en) | 2004-02-11 |
| WO1999051244A1 (en) | 1999-10-14 |
| DK1069902T3 (da) | 2004-06-07 |
| CA2327693C (en) | 2006-11-21 |
| US6719960B1 (en) | 2004-04-13 |
| ES2214748T3 (es) | 2004-09-16 |
| DE69821655D1 (de) | 2004-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69821655T2 (de) | Verwendung von phospholipiden zur herstellung eines arzneimittels zur vorbeugung von adhäsionen | |
| DE69807420T2 (de) | Pharmazeutische aerosolzusammensetzung | |
| DE69005951T2 (de) | Medikamente enthaltend Salmeterol und Fluticason. | |
| DE60132828T2 (de) | Zusammensetzung enthaltend Formoterol und ein Glucocorticosteroid | |
| DE69936730T2 (de) | Lösungsaerosolzusammensetzungen, die HFA227 und HFA 134a enthalten | |
| DE69033856T2 (de) | Verabreichungssystem für phospholipide | |
| DE69332240T2 (de) | Ultrafeines pulver zur inhalation und dessen herstellung | |
| DE69233319T2 (de) | Aerosolzusammensetzungen für Arzneimittelsuspensionen | |
| DE60019167T2 (de) | Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason | |
| DE69603577T2 (de) | Verfahren und vorrichtung zur verabreichung von analgetika | |
| DE69735497T2 (de) | Medizinische aerosolformulierungen enthaltend budesonid | |
| DE69629591T2 (de) | Formulierung zur intranasalen verabreichung | |
| DE69233076T3 (de) | Aerosolpräparate | |
| DE69511374T2 (de) | Neue und verbesserte aminoglykosidformulierung als aerosol | |
| DE60003162T2 (de) | Modifizierte trägerpartikel zur verwendung in trockenpulverinhalatoren | |
| DE69609834T2 (de) | Kontinuierliche mikrodispersionen von fluorierten verbindungen zur verabreichung von pharmazeutischen stoffen | |
| DE69631119T2 (de) | Pulver zur verwendung in trockenpulverinhalatoren | |
| DE69330672T2 (de) | Pharmazeutische zubereitung zur anwendung in den atemwegen | |
| DE69323428T2 (de) | Morphinzubereitungen mit kontrollierter freisetzung | |
| AT389993B (de) | Herstellung von aerosolzusammensetzungen | |
| DE69205177T2 (de) | Pharmazeutische Aerosolformulierung. | |
| DE69227257T2 (de) | Arzneimittel | |
| EP1014943A1 (de) | Medizinische aerosolformulierungen | |
| WO1996010389A1 (de) | Pharmazeutische zusammensetzung | |
| EP2110126A1 (de) | Inhalative und instillative Verwendung von semifluorierten Alkanen als Wirkstoffträger im intrapulmonalen Bereich |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |